Meta Pixel

News and Announcements

Stop Chasing VCs, Go After Angel Investors Instead

  • Published December 14, 2022 6:31AM UTC
  • Publisher Osama Hassan
  • Categories Capital Raising Tips

Most first-time founders automatically think that VCs are where it’s at. The crucial thing about venture, though, is the investment criteria.

VCs are only interested in the tiniest minority of ideas. In some ways, it doesn’t actually matter how likely you are to succeed. If your startup doesn’t tick the “power law” box (the law states that the vast majority of returns come from a tiny minority of deals), there’s almost no chance a VC will invest in you, even if your business is a sure thing.

Most founders waste far too much time chasing VCs, when they’d be far better speaking with angel investors and family offices. Granted, they’re harder to find, but they’re also more likely to invest. For VCs, there’s no such thing as medium success. For them, an investment is either a game changer or it’s a statistic.

🙌

Click here to view the original Linkedin post.

Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.

Your capital engagement platform

With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now